Cathelicidin LL-37 bloodstream surveillance is down regulated during septic shock

Microbes and Infection

Volumn 15, Issue 5, 2013, Pages 342-346

  Barbeiro, Denise Frediani ^a   Barbeiro, Hermes Vieira ^a   Zampieri, Fernando Godinho ^a   César Machado, Marcel Cerqueira ^a   Torggler Filho, Francisco ^a   Gomes Cunha, Débora Maria ^a   Goulart, Alessandra Carvalho ^a   Velasco, Irineu Tadeu ^a   Monteiro da Cruz Neto, Luiz ^a   Possolo de Souza, Heraldo ^a   Pinheiro da Silva, Fabiano ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cathelicidin; Inflammation; Sepsis; Vitamin D

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D RECEPTOR;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY MECHANISM; SEPTIC SHOCK; VITAMIN BLOOD LEVEL;

ADULT; AGED; ANTIMICROBIAL CATIONIC PEPTIDES; COHORT STUDIES; DOWN-REGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SHOCK, SEPTIC; VITAMIN D;

BACTERIA (MICROORGANISMS);

EID: 84876857721     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2013.01.001     Document Type: Article

References (31)

1. Pinheiro da Silva F., Machado M.C. Antimicrobial peptides: clinical relevance and therapeutic implications. Peptides 2012, 36:308-314.
2. Nizet V., Ohtake T., Lauth X., Trowbridge J., Rudisill J., Dorschner R.A., Pestonjamasp V., Piraino J., Huttner K., Gallo R.L. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001, 414:454-457.
3. Iimura M., Gallo R.L., Hase K., Miyamoto Y., Eckmann L., Kagnoff M.F. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J. Immunol. 2005, 174:4901-4907.
4. Chromek M., Slamova Z., Bergman P., Kovacs L., Podracka L., Ehren I., Hokfelt T., Gudmundsson G.H., Gallo R.L., Agerberth B., Brauner A. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 2006, 12:636-641.
5. Huang L.C., Jean D., Proske R.J., Reins R.Y., McDermott A.M. Ocular surface expression and in vitro activity of antimicrobial peptides. Curr. Eye Res. 2007, 32:595-609.
6. Oren Z., Lerman J.C., Gudmundsson G.H., Agerberth B., Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem. J. 1999, 341(Pt 3):501-513.
7. Scott M.G., Davidson D.J., Gold M.R., Bowdish D., Hancock R.E. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. 2002, 169:3883-3891.
8. Kurosaka K., Chen Q., Yarovinsky F., Oppenheim J.J., Yang D. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol. 2005, 174:6257-6265.
9. Dorschner R.A., Pestonjamasp V.K., Tamakuwala S., Ohtake T., Rudisill J., Nizet V., Agerberth B., Gudmundsson G.H., Gallo R.L. Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol. 2001, 117:91-97.
10. Koczulla R., von Degenfeld G., Kupatt C., Krotz F., Zahler S., Gloe T., Issbrucker K., Unterberger P., Zaiou M., Lebherz C., Karl A., Raake P., Pfosser A., Boekstegers P., Welsch U., Hiemstra P.S., Vogelmeier C., Gallo R.L., Clauss M., Bals R. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 2003, 111:1665-1672.
11. Zheng Y., Niyonsaba F., Ushio H., Nagaoka I., Ikeda S., Okumura K., Ogawa H. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils. Br. J. Dermatol. 2007, 157:1124-1131.
12. Scott A., Weldon S., Buchanan P.J., Schock B., Ernst R.K., McAuley D.F., Tunney M.M., Irwin C.R., Elborn J.S., Taggart C.C. Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS One 2011, 6:e26525.
13. Mookherjee N., Brown K.L., Bowdish D.M., Doria S., Falsafi R., Hokamp K., Roche F.M., Mu R., Doho G.H., Pistolic J., Powers J.P., Bryan J., Brinkman F.S., Hancock R.E. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 2006, 176:2455-2464.
14. Bowdish D.M., Davidson D.J., Speert D.P., Hancock R.E. The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J. Immunol. 2004, 172:3758-3765.
15. R.C. Bone, R.A. Balk, F.B. Cerra, R.P. Dellinger, A.M. Fein, W.A. Knaus, R.M. Schein, W.J. Sibbald, Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, in: The ACCP/SCCM consensus conference committee, American College of Chest Physicians/Society of Critical Care Medicine, Chest 101, 1992, pp. 1644-1655.
16. Liu P.T., Stenger S., Li H., Wenzel L., Tan B.H., Krutzik S.R., Ochoa M.T., Schauber J., Wu K., Meinken C., Kamen D.L., Wagner M., Bals R., Steinmeyer A., Zugel U., Gallo R.L., Eisenberg D., Hewison M., Hollis B.W., Adams J.S., Bloom B.R., Modlin R.L. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
17. Oppenheim J.J., Tewary P., de la Rosa G., Yang D. Alarmins initiate host defense. Adv. Exp. Med. Biol. 2007, 601:185-194.
18. Oppenheim J.J., Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 2005, 17:359-365.
19. Schauber J., Dorschner R.A., Yamasaki K., Brouha B., Gallo R.L. Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 2006, 118:509-519.
20. Bals R., Weiner D.J., Moscioni A.D., Meegalla R.L., Wilson J.M. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect. Immun. 1999, 67:6084-6089.
21. Cirioni O., Giacometti A., Ghiselli R., Bergnach C., Orlando F., Silvestri C., Mocchegiani F., Licci A., Skerlavaj B., Rocchi M., Saba V., Zanetti M., Scalise G. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob. Agents Chemother. 2006, 50:1672-1679.
22. Pinheiro da Silva F., Gallo R.L., Nizet V. Differing effects of exogenous or endogenous cathelicidin on macrophage toll-like receptor signaling. Immunol. Cell. Biol. 2009, 87:496-500.
23. Berkestedt I., Herwald H., Ljunggren L., Nelson A., Bodelsson M. Elevated plasma levels of antimicrobial polypeptides in patients with severe sepsis. J. Innate Immun. 2010, 2:478-482.
24. Ng G., Sharma K., Ward S.M., Desrosiers M.D., Stephens L.A., Schoel W.M., Li T., Lowell C.A., Ling C.C., Amrein M.W., Shi Y. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 2008, 29:807-818.
25. Lee C.C., Sun Y., Qian S., Huang H.W. Transmembrane pores formed by human antimicrobial peptide LL-37. Biophys. J. 2011, 100:1688-1696.
26. Brown K.L., Poon G.F., Birkenhead D., Pena O.M., Falsafi R., Dahlgren C., Karlsson A., Bylund J., Hancock R.E., Johnson P. Host defense peptide LL-37 selectively reduces proinflammatory macrophage responses. J. Immunol. 2011, 186:5497-5505.
27. Bowdish D.M., Davidson D.J., Hancock R.E. A re-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 2005, 6:35-51.
28. Jeng L., Yamshchikov A.V., Judd S.E., Blumberg H.M., Martin G.S., Ziegler T.R., Tangpricha V. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J. Transl Med. 2009, 7:28.
29. Carretero M., Escamez M.J., Garcia M., Duarte B., Holguin A., Retamosa L., Jorcano J.L., Rio M.D., Larcher F. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J. Invest. Dermatol. 2008, 128:223-236.
30. Hancock R.E., Nijnik A., Philpott D.J. Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol. 2012, 10:243-254.
31. Mookherjee N., Rehaume L.M., Hancock R.E. Cathelicidins and functional analogues as antisepsis molecules. Expert Opin. Ther. Targets 2007, 11:993-1004.